Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
暂无分享,去创建一个
P. Zinzani | M. Dreyling | B. Childs | F. Morschhauser | D. Bron | U. Vitolo | K. Linton | K. Bouabdallah | E. Neste | S. Mappa | M. Giurescu